Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McLaughlin

Showing results (691-700 of 726) with videos related to

Pageof 73
Sort By:
Brain Research|January 9, 2001
LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemiaM J O'Neill, C A Hicks, M A Ward, et al.
Plos Biology|June 19, 2013
Parasites affect food web structure primarily through increased diversity and complexityJennifer A Dunne, Kevin D Lafferty, Andrew P Dobson, et al.
Breast (Edinburgh, Scotland)|June 25, 2021
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort studyMatthew G Davey, Eoin Kerin, C O'Flaherty, et al.
Blood|December 12, 2001
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityI F Khouri, R M Saliba, S A Giralt, et al.
Public Health Reports (Washington, D.C. : 1974)|February 9, 2022
Acceptance of Saliva-Based Specimen Collection for SARS-CoV-2 Testing Among K-12 Students, Teachers, and StaffHeather P McLaughlin, Mary Claire Worrell, Sara Malone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programP McLaughlin, A J Grillo-López, B K Link, et al.
Biology Letters|March 2, 2018
Local extinction of the Asian tiger mosquito (<i>Aedes albopictus</i>) following rat eradication on Palmyra AtollKevin D Lafferty, John P McLaughlin, Daniel S Gruner, et al.
European Journal of Medicinal Chemistry|January 7, 2015
Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activitiesMiao Hu, Marc A Giulianotti, Jay P McLaughlin, et al.
Molecules (Basel, Switzerland)|July 12, 2025
Dual Opioid-Neuropeptide FF Small Molecule Ligands Demonstrate Analgesia with Reduced Tolerance LiabilitiesMarco Mottinelli, V Blair Journigan, Samuel Obeng, et al.
Pageof 73

Showing results (691-700 of 726) with videos related to

Sort By:
Pageof 73
Brain Research|January 9, 2001
LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemiaM J O'Neill, C A Hicks, M A Ward, et al.
Plos Biology|June 19, 2013
Parasites affect food web structure primarily through increased diversity and complexityJennifer A Dunne, Kevin D Lafferty, Andrew P Dobson, et al.
Breast (Edinburgh, Scotland)|June 25, 2021
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort studyMatthew G Davey, Eoin Kerin, C O'Flaherty, et al.
Blood|December 12, 2001
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityI F Khouri, R M Saliba, S A Giralt, et al.
Public Health Reports (Washington, D.C. : 1974)|February 9, 2022
Acceptance of Saliva-Based Specimen Collection for SARS-CoV-2 Testing Among K-12 Students, Teachers, and StaffHeather P McLaughlin, Mary Claire Worrell, Sara Malone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programP McLaughlin, A J Grillo-López, B K Link, et al.
Biology Letters|March 2, 2018
Local extinction of the Asian tiger mosquito (<i>Aedes albopictus</i>) following rat eradication on Palmyra AtollKevin D Lafferty, John P McLaughlin, Daniel S Gruner, et al.
European Journal of Medicinal Chemistry|January 7, 2015
Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activitiesMiao Hu, Marc A Giulianotti, Jay P McLaughlin, et al.
Molecules (Basel, Switzerland)|July 12, 2025
Dual Opioid-Neuropeptide FF Small Molecule Ligands Demonstrate Analgesia with Reduced Tolerance LiabilitiesMarco Mottinelli, V Blair Journigan, Samuel Obeng, et al.
Pageof 73